Connect with us

Technology

High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape – Technavio

Published

on

NEW YORK, Jan. 31, 2025 /PRNewswire/ — Report with market evolution powered by AI – The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

High Throughput Screening (HTS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.12%

Market growth 2024-2028

USD 19.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

11.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Japan, China, Germany, and France

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector’s quest to develop new products and services for the detection and treatment of chronic diseases. 

The High Throughput Screening (HTS) market presents unique challenges for vendors due to its specialized nature and niche end-users. Brand and product visibility play a limited role in sales, and advertising and marketing are restricted. Key players in the industry recognize this issue and are promoting HTS through their websites and additional support materials. Thermo Fisher Scientific, for instance, provides explanatory documents, brochures, and interactive videos on YouTube to help end-users understand the technique better. Despite these efforts, there is a significant lack of awareness about HTS. Vendors must focus on improving their distribution networks to make these products readily available to end-users. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

High-throughput screening (HTS) is a crucial process in the biotechnology industry, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. The market for HTS is vast and diverse, with players including academic institutions, biotech startups, and pharmaceutical corporations. Challenges in this field include managing large data sets from compound libraries, dealing with false-positive findings, and maintaining specialized equipment. HTS involves the use of automation, robotics, and specialized instruments like microplate readers and high-resolution imaging systems. Data analytics is essential for making sense of the vast amounts of data generated. Machine learning and data management systems help in data organization, retrieval, integration, and storage. HTS is not just limited to pharmaceutical companies but also extends to the global healthcare sector, research organizations, and contract research organizations. Collaborative networks and HTS service providers play a significant role in driving innovation through open innovation models. HTS is also used in stem cell research, toxicology, and drug development. HTS involves various techniques like cell-based assays, lab-on-a-chip, and label-free technology. Biochemical screening and target identification are critical components of the HTS process. Drug repurposing initiatives, such as those from Relay Therapeutics, are gaining popularity in the biopharmaceutical industry due to their potential to bring new drugs to market faster and more cost-effectively. The HTS market is expected to grow significantly due to the increasing focus on precision medicine and the need for new drugs to address chronic diseases. Consumables, software, and services are essential products and services in the HTS market. The use of technology in HTS, such as automation and advanced detection techniques, is transforming the drug discovery process. Despite the challenges, the future of HTS looks promising, with advancements in technology and a growing focus on collaboration and open innovation models. The use of HTS in drug discovery and development is expected to revolutionize the way we approach complex illnesses and bring new treatments to market.In today’s fast-paced pharmaceutical and biotechnology industries, High Throughput Screening (HTS) has become a crucial tool for discovering new drugs and optimizing existing ones. However, the successful implementation of HTS relies heavily on the availability of skilled personnel. The shortage of trained professionals in this field can lead to non-compliance and improper screening of drug targets. Consequently, product failures and regulatory issues can result in significant financial losses for companies. This issue is particularly prevalent in developing countries, where the healthcare system lacks the necessary workforce to effectively utilize HTS technology. To mitigate this challenge, it is essential for organizations to invest in training and development programs for their staff, ensuring they have the necessary expertise to operate HTS equipment effectively and efficiently.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This high throughput screening (HTS) market report extensively covers market segmentation by  

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global high throughput screening (HTS) market is driven by the increasing need for target identification and validation in drug development. This process involves finding potential therapeutic targets for diseases or conditions without existing treatments or inadequate current options. Early and thorough target identification and validation establish a strong link to clinical trial success. Chronic diseases like cardiovascular diseases, cancer, and respiratory diseases, which have a high global prevalence, fuel the demand for new targets. Additionally, the growing pipeline for biological candidates, outsourcing from pharmaceutical companies, and regulatory agencies’ demand for accurate drug and process development details contribute to market expansion. Advanced bioinformatics tools, automated experimental designs, and AI/ML algorithms are enhancing target identification and validation, further boosting the segment’s growth. Consequently, these factors are expected to fuel the growth of the target identification and validation segment in the global high throughput screening market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

High-throughput screening (HTS) is a critical technology in the global healthcare sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, often containing hundreds of thousands to millions of compounds, which are screened against disease targets using automated systems. These systems include robotic arms, microplate readers, and high-resolution imaging systems. Data analytics plays a crucial role in HTS, with data management systems, data storage, data organization, data retrieval, data integration, and chemical databases essential for processing and interpreting the vast amounts of data generated. Academic institutions, biotech startups, research organizations, and pharmaceutical corporations all contribute to the HTS market, with open innovation models facilitating collaboration and knowledge sharing. Drug repurposing, the process of discovering new uses for existing drugs, is also a significant application of HTS. The market for HTS is expected to grow significantly due to the increasing demand for new and effective treatments for various diseases.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, store, retrieve, integrate, and analyze genomic data and chemical databases. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives and biopharmaceutical industry leaders are leveraging HTS for precision medicine and target identification, while toxicology and stem cell research also benefit from this technology. The global healthcare sector continues to invest in HTS for drug discovery, clinical trials, and product development, driving the market for instruments, software, and consumables.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-to-grow-by-usd-19-9-billion-2024-2028-boosted-by-rising-rd-investments-with-ai-redefining-market-landscape—technavio-302364447.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Industry leaders to join forces to scale hydrogen mobility

Published

on

By

Volvo Group

For the first time in Europe, Germany is bringing together the full ecosystem needed to scale the deployment of hydrogen trucks by 2030, combining supportive policy frameworks, a strong OEM offering and an integrated hydrogen supply chain and infrastructure.Volvo Group, Daimler Truck, Toyota Motor Corporation, Bosch, Air Liquide, TotalEnergies, TEAL Mobility, MB Energy, and more companies accelerate the commercialization of hydrogen-powered mobility and build the ecosystem needed to scale it along the whole value chain, with vehicles, infrastructure and supply. The activities include the deployment of hydrogen refueling stations along key strategic corridors in Europe, in synchronization with the hydrogen-powered truck fleets as well as a competitive hydrogen price. This will enable customers to operate hydrogen-powered vehicles with a competitive total cost of ownership. Full details will be unveiled at a CEO-led press event during IAA Transportation in Hanover on 15 September.

GOTHENBURG, Sweden, Sept. 3, 2026 /PRNewswire/ — Leading companies from the transport, energy and industrial sectors, together with German policymakers, are collaborating to establish a benchmark for a fully integrated hydrogen mobility ecosystem for heavy-duty transport. They reflect a shared ambition to scale hydrogen with a focus on customer-oriented refueling infrastructure and competitively priced hydrogen fuel.

Delivering a comprehensive hydrogen ecosystem that complements battery-electric solutions requires coordinated development across the entire value chain with focus on commercializing competitive vehicles, deploying strategically located refueling infrastructure aligned with customer needs, and ensuring reliable access to hydrogen at viable price levels. Together, these elements can create the conditions for a competitive total cost of ownership and position hydrogen as a practical, scalable solution for zero-emission transport.

Further details will be announced on September 15 at IAA Transportation 2026.

Volvo Group, Daimler Truck, Toyota Motor Corporation, Bosch, Air Liquide, TotalEnergies, TEAL Mobility, MB Energy

September 3, 2026

Journalists wanting further information, please contact:
Claes Eliasson, Head of Media Relations
+46 76 553 7229
press@volvo.com

For more information, please visit volvogroup.com
For frequent updates, follow us on LinkedIn

The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs almost 100,000 people and serves customers in almost 180 markets. In 2025, net sales amounted to SEK 479 billion (EUR 43 billion). Volvo shares are listed on Nasdaq Stockholm.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/ab-volvo/r/industry-leaders-to-join-forces-to-scale-hydrogen-mobility,c4391363

The following files are available for download:

https://mb.cision.com/Main/39/4391363/4249230.pdf

Press release — Industry leaders to join forces to scale hydrogen mobility

https://news.cision.com/ab-volvo/i/1860×1050-iaa-pr,c3561719

1860×1050 IAA PR

 

View original content:https://www.prnewswire.com/news-releases/industry-leaders-to-join-forces-to-scale-hydrogen-mobility-302868716.html

SOURCE AB Volvo

Continue Reading

Technology

CFD Broker Mitrade EU Introduces Excess-of-Loss Insurance Protection for Its Clients

Published

on

By

LIMASSOL, Cyprus, Sept. 3, 2026 /PRNewswire/ — CFD broker Mitrade has arranged additional insolvency insurance for eligible clients onboarded under its CySEC licence. The initiative reflects a broader focus on strengthening client confidence and investor protection.

This excess-of-loss policy supplements protections CySEC already mandates. CySEC-authorised investment firms are required to segregate client funds and contribute to the Investor Compensation Fund. Beyond those statutory safeguards, Mitrade EU Limited’s discretionary insurance coverage has been arranged through Lloyd’s of London and funded by Mitrade. It is automatically available to eligible clients without an opt-in requirement or additional client charge.

Should Mitrade EU Limited become insolvent, the policy may cover eligible claims, subject to its terms, conditions and exclusions, up to a maximum aggregate amount of €1 million across all claims combined. It does not cover trading losses or losses caused by market movements.

“Regulation sets the baseline; we decide how much further to go for clients,” said Timur Konsky, CEO of Mitrade EU. “That is why we put additional insurance in place with Lloyd’s of London. Our approach is to identify where clients can be protected and take steps to reduce those risks. Transparency and safety should not be marketing language; they should be demonstrated through the safeguards a broker chooses to put in place. We want our clients to judge us by our actions, and this policy is another concrete example of that commitment.”

Mitrade EU’s excess-of-loss insurance cover takes effect from 1 September 2026.

About Mitrade 

Mitrade is a CFD trading platform operating in eligible EEA markets through Mitrade EU Limited, a CySEC-authorised investment firm (CIF438/23). Other legally separate entities within the international group are independently authorised and regulated in their respective jurisdictions by ASIC (AFSL398528), CIMA (SIB1612446), FSCA (FSP54842), FSC (GB20025791), and CMA (20200000397). 

Globally, the brand connects 7M+ traders to 1,000+ CFDs on indices, forex, commodities, shares, ETFs and more. The platform is designed to provide fast execution, flexible leverage on a per-position basis, competitive spreads and an intuitive interface accessible across multiple devices. 

Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. 

Visit https://www.mitrade.eu for more information.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cfd-broker-mitrade-eu-introduces-excess-of-loss-insurance-protection-for-its-clients-302867016.html

Continue Reading

Technology

Aurra Markets Receives ‘Most Transparent Broker’ Award in Mumbai

Published

on

By

Aurra Markets wins the ‘Most Transparent Broker’ award at Money Expo Mumbai 2026. Read about our MT5 infrastructure and Aurra Wallet.

MUMBAI, India, Sept. 3, 2026 /PRNewswire/ — Aurra Markets Wins ‘Most Transparent Broker’ Award at Money Expo Mumbai

Aurra Markets, a multi-asset CFD broker, received the ‘Most Transparent Broker’ award at Money Expo Mumbai 2026. Participating as a Diamond Sponsor at the Jio World Convention Centre, the brokerage presented its institutional-grade trading infrastructure and partnership models to the Indian financial community.

Direct Market Access and Tier-1 Liquidity

Receiving this award reflects the company’s focus on maintaining secure trading conditions. In active financial markets, reliability is a primary requirement for retail and institutional traders. By integrating direct Tier-1 liquidity and holding fully segregated client funds, Aurra Markets provides a stable environment for trading forex, precious metals, and indices. The team demonstrated its MetaTrader 5 (MT5) framework at Booth 33, highlighting the 12ms execution speed that supports algorithmic and day traders.

Efficient Funding via the Aurra Wallet

The exhibition also served as a platform to detail the company’s advanced funding infrastructure. Clients can manage their capital using the Aurra Wallet. This unified system bridges fiat and digital assets, allowing traders to handle deposits and withdrawals efficiently. Integrating this technology reduces banking delays and provides rapid market access.

Expanding Operations in the Indian Market

“We are honored to receive the Most Transparent Broker award in Mumbai,” a senior spokesperson for Aurra Markets stated. “This recognition validates our infrastructural investments designed to lower trading costs and maintain security. Engaging with affiliates and traders in India confirms the demand for high-performance trading solutions. We provide market participants with the stability needed to trade macroeconomic shifts.”

About Aurra Markets

Aurra Global Markets Limited is authorized and regulated by the Mauritius Financial Services Commission (FSC) under License No. GB25204837. Aurra Markets provides a global community of traders with the direct infrastructure and technical resources needed to operate in dynamic financial markets. For more information, visit www.aurra.markets.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurra-markets-receives-most-transparent-broker-award-in-mumbai-302868741.html

SOURCE AURRA GLOBAL MARKETS LIMITED

Continue Reading

Trending